Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Scottish Medicines Consortium approves Libtayo as second-line treatment for advanced cervical cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, ...
SMITH COUNTY, Texas (KLTV) - A Smith County jury sentenced a Longview parolee to 60 years in prison on drug charges. Wednesday ... 100 multicolored meth pills shaped like various superhero logos and ...
If approved, this combination therapy could provide a new first-line treatment option for patients with advanced liver cancer ... the combination of Opdivo (nivolumab) and Yervoy (ipilimumab ...
Hepatocellular carcinoma, the most common type of liver cancer ... drug Sotyktu for treating active psoriatic arthritis, marking a significant advancement in rheumatic conditions. It has also obtained ...
The company has successfully completed Phase 3 trials of its drug Sotyktu ... for the use of Opdivo and Yervoy as a first-line treatment for certain types of colorectal cancer.
Different parts of Medicare can provide coverage for cancer ... Opdivo infusions that a person gets as an outpatient in a health center or doctor’s clinic. Medicare Part D covers prescription ...
NEW YORK – Recent data on the efficacy of the combination of Bristol Myers Squibb's Opdivo (nivolumab) and Yervoy (ipilimumab) suggest it could be a new standard first-line option for metastatic ...
CheckMate -8HW is a multinational, open-label, randomized trial that enrolled patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR. Participants were randomly assigned in a 2:2 ...
Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced the risk of disease progression or death by 38% in a Phase 3 trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback